Clinical trials: Camrelizumab
Breast Neoplasms
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
RATIONALE: Patients with HER2-negative advanced breast cancer have limited choice on targeted therapies, and often show only modest responses to available immunotherapies.
- Trial name
- NCT05981001
- Testing
- Surgery for harvesting tumor-draining lymph nodes, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Esophageal Cancer
A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC
The purpose of this study is to assess efficacy and safety of patients who receive camrelizumab as consolidation therapy after radical concurrent chemoradiotherapy in locally advanced ESCC.
- Trial name
- ESCC (NCT04286958)
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hebei Medical University Fourth Hospital
Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC)
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC).
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
- Trial name
- FAD-HCC-001 (NCT07314372)
- Testing
- Camrelizumab Plus Apatinib, TACE Plus Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 86 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Advanced Esophageal Squamous Carcinoma With Oligometastases
Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases.
A randomized, prospective phase II trial was conducted to explore the timing of radiotherapy intervention in combination with chemotherapy and immunotherap in order to provide an effective treatment for patients with advanced…
- Trial name
- NCT06143722
- Testing
- simultaneous with radiotherapy, synchronous with radiotherapy
- Volunteers
- 63 people
- Sponsor
- West China Hospital
Breast Cancer
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
This is a phase II, open-labeled, multi-centered,single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with apatinib (a VEGFR2 TKI) and eribulin mesylate in patients with…
- Trial name
- NCT04303741
- Testing
- Camrelizumab, Apatinib, Eribulin
- Where
- 3 sites in China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hodgkin Lymphoma
Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen
The DP regimen, low-dose decitabine combined with SHR-1210, is the new treatment for relapsed or refractory classical Hodgkin's Lymphoma.
- Trial name
- NCT04026269
- Testing
- MOAP
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Han weidong
Non-Small Cell Lung Cancer, Chemotherapy
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
Chemotherapeutic agents exert significant immunomodulatory effects by influencing tumor-infiltrating immune cells. However, the sequence and combination of chemotherapy regimens differentially modulate immune cell dynamics…
- Conditions
- Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
- Trial name
- NCT06896422
- Testing
- Glutathione, PD1 Inhibitor, Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Melanoma
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene…
- Trial name
- NCT05983237
- Testing
- Fluzoparib Camrelizumab Temozolomide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jun Guo
Gastric Cancer, RWS
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer…
- Conditions
- Gastric Cancer, RWS, PD-1 Immunotherapy
- Trial name
- NCT06485271
- Testing
- Camrelizumab, apatinib, chemotherapy
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Changzhi People's Hospital Affiliated to Changzhi Medical College
Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
The objective of this study is to investigate the safety and tolerability of camrelizumab combined with apatinib and chemotherapies (gemcitabine and cisplatin) in patients with advanced biliary tract cancer (BTC).
- Trial name
- HP-BTC-001 (NCT05742750)
- Testing
- Camrelizumab and Apatinib Plus GP
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Sun Yat-sen University
Advanced NSCLC
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in Advanced NSCLC.
- Trial name
- NCT05106335
- Testing
- camrelizumab + famitinib, famitinib, docetaxel
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Macrotrabecular Massive Hepatocellular Carcinoma
A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC
This is a single-arm, open, multicenter II phase clinical study to compare the efficacy and safety of HAIC combined with Apatinib and Camrelizumab in the treatment of unresectable middle-advanced MTM-HCC.
- Trial name
- CCGLC-010 (NCT05839197)
- Testing
- HAIC, Camrelizumab plus Apatinib
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Wan-Guang Zhang
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
This study is designed to explore the efficacy and safety of surufatinib combined with camrelizumab and AS (nab-paclitaxel and S-1) as first-line treatment compared with AG (nab-paclitaxel and gemcitabine) in unresectable…
- Conditions
- Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Pancreatic Neoplasms
- Trial name
- NCT05218889
- Testing
- surufatinib + camrelizumab + nab-paclitaxel + S-1, nab-paclitaxel + gemcitabine
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese PLA General Hospital
Hepatecellular Carcinoma
Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study
1.1. Main Objectives The objective response rate (ORR) determined by the researchers based on RECIST v1.1 was used to evaluate the efficacy of systemic therapy (carrycept combined with apatinib) in combination with or without…
- Trial name
- NCT07482670
- Volunteers
- 32 people
- Sponsor
- Xiangya Hospital of Central South University
Recurrent or Metastatic Nasopharyngeal Carcinoma
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
This is a prospective, Bayesian adaptive, phase II clinical trial designed to evaluate the safety and efficacy of four treatment regimens in patients with recurrent (unamenable to local therapy) or metastatic nasopharyngeal…
- Trial name
- NCT07070479
- Testing
- Ivonescimab, Nimotuzumab, Irinotecan liposome
- Where
- 6 sites in China
- Volunteers
- 208 people
- Sponsor
- Ming-Yuan Chen
Primary Mediastinal Large B-cell Lymphoma
Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs
This is a two stage, Phase I/II clinical trial for patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL).
- Trial name
- NCT03346642
- Testing
- Decitabine, GVD chemotherapy, SHR-1210
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
The purpose of this study is to explore the efficacy and safety of SHR-1210 in combination with apatinib in treating patients with metastatic, persistent, or recurrent cervical cancer.
- Trial name
- NCT03816553
- Testing
- SHR-1210, Apatinib
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Breast Cancer Stage IV, Triple -Negative Breast Cancer
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall…
- Trial name
- NCT06889688
- Testing
- Camrelizumab+Apatinib+Eribulin, Physician's choice chemotherapy
- Where
- 7 sites in China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Triple-negative Breast Cancer
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.
- Trial name
- NCT05749588
- Testing
- A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab with famitinib, B1: TROP2 ADC
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
An exploratory phase II trial of immune checkpoint inhibitors (ICIs, anti-PD-1/anti-PD-L1) as second-line treatment with advanced non-small cell lung cancer (NSCLC) who had long-term response to first-line immunotherapy (with or…
- Trial name
- NCT06388031
- Testing
- Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Peking Union Medical College Hospital